Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Production / Operations Routine +

Ynvisible Secures SEK 3.0 Million in Grants to Advance Sustainable Manufacturing and Medical E-Paper Applications

Ynvisible Secures Incremental Grant Funding Amidst Continued Dilution and Commercial Scaling Phase

By The Northwire Desk — AI Analysis May 28, 2026 · 14:24 YNV · 0.105 Ynvisible Interactive Inc.
Executive Summary
  • Ynvisible Interactive Inc. secured SEK 3.0 million (approx. CAD$400,000) in grants from Swedish innovation organizations on May 28, 2026.
  • Funding is allocated to two specific projects: R2R-MICROBAT for battery manufacturing and MedPrint for medical-grade e-paper display production.
  • The MedPrint initiative targets a potential capacity of up to 10 million units annually in Norrköping.
  • Management views the funding as validation of their sustainable manufacturing capabilities and expansion into healthcare diagnostics.
  • This follows a series of private placements closed between March and May 2026, totaling over $1.3 million in gross proceeds from equity financing.
Material Impact
  • The grant represents non-dilutive capital which is positive for cash flow but immaterial relative to the company's overall burn rate and recent equity dilution.
  • Previous private placements (March-May 2026) raised approximately $1.3 million in equity, indicating a reliance on shareholder capital rather than commercial revenue to fund operations.
  • The grant amount ($400k) is roughly equivalent to one month of the previous financing rounds and does not materially alter the company's runway or valuation thesis compared to the dilution risk from recent financings.
  • News aligns with historical projections regarding MedPrint scaling; no new commercial contracts were announced alongside this funding, limiting immediate revenue impact.
  • Market reaction has been muted historically on similar announcements (price remained flat around $0.10-$0.12 during financing closings in April/May 2026).
YNV · Price
Company Overview
  • Core Business: Ynvisible develops ultra-low power printed e-paper displays for healthcare, industrial, and automotive applications.
  • Flagship Projects: MedPrint (medical diagnostics) and R2R-MICROBAT (sustainable battery manufacturing).
  • Manufacturing: Operates a roll-to-roll facility in Norrköping, Sweden; utilizes CCL Design for high-volume production transfer to China.
  • Commercial Status: Transitioned from development to commercial execution in 2025 with ~12 confirmed orders generating CAD$800k revenue; pipeline quoted value estimated at CAD$30 million but conversion rate remains unverified.
Read the original news release →

More from Ynvisible Interactive Inc.

Jun 10, 2026 · 02:01

Low-volume commercial execution continues to outpace revenue recognition in a cash-burn, going-concern environment.

Production / Operations Jun 04, 2026 · 15:26

Ynvisible extends private placement deadline to July 2026 as it pursues medical and automotive e-paper growth

Financings May 13, 2026 · 17:17

Ynvisible Secures Insider-Backed Capital at Premium to Market Amidst Downtrend

Financings Apr 24, 2026 · 15:51

Ynvisible Secures Working Capital Amidst Dilution Concerns and Commercial Ramp-Up

Financings Mar 31, 2026 · 16:12

Ynvisible Closes Tranche Two of Dilutive Financing as Cash Burn Outpaces Commercial Traction

Financings Mar 26, 2026 · 18:51

Ynvisible closes $577,000 first tranche of placement

Financings